AXQ Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

AXQ Capital LP lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 123.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,541 shares of the biopharmaceutical company’s stock after purchasing an additional 852 shares during the quarter. AXQ Capital LP’s holdings in Regeneron Pharmaceuticals were worth $809,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. PGGM Investments increased its stake in Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Founders Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after buying an additional 538 shares in the last quarter. Sepio Capital LP grew its holdings in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 842 shares during the last quarter. Generate Investment Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $6,300,000. Finally, Bellecapital International Ltd. raised its holdings in Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after acquiring an additional 6,283 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on REGN shares. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $776.81.

Regeneron Pharmaceuticals Trading Up 2.6%

NASDAQ:REGN opened at $755.90 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $800.99. The business has a fifty day moving average price of $615.29 and a 200-day moving average price of $575.72. The firm has a market capitalization of $79.44 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the business posted $12.46 earnings per share. The business’s quarterly revenue was up .9% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.